Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Esperion Theraptc
(NQ:
ESPR
)
1.770
+0.060 (+3.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Esperion Theraptc
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Esperion Therapeutics's Earnings Outlook
February 20, 2023
Via
Benzinga
Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
February 20, 2023
– NEXLETOL® (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint –
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 13, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
February 07, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Recap: Esperion Therapeutics Q3 Earnings
November 01, 2022
Esperion Therapeutics (NASDAQ:ESPR) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Esperion Therapeutics: Q2 Earnings Insights
August 02, 2022
Esperion Therapeutics (NASDAQ:ESPR) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via
Benzinga
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
January 11, 2023
NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
January 08, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Top Picks For 2023: Esperion
January 02, 2023
Esperion is a de-risked biotech company in the cardiovascular sector with its lead drug, bempedoic acid, already FDA approved to reduce LDL cholesterol. Let's take a closer look at why it's a top pick...
Via
Talk Markets
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
December 19, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 13, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in January Investor Meetings
December 13, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Therapeutics Reports Sooner Than Expected Positive Data From Nexletol Trial
December 07, 2022
Via
Benzinga
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
December 07, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Appoints Ben Halladay Chief Financial Officer
November 16, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Therapeutics's Return On Capital Employed Insights
November 09, 2022
According to data from Benzinga Pro, during Q3, Esperion Therapeutics's (NASDAQ:ESPR) reported sales totaled $18.98 million. Despite a 16.9% increase in earnings, the company posted a loss of $55.12...
Via
Benzinga
Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
November 09, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Jefferies London Healthcare Conference
November 02, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update
November 01, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Hosting Virtual Research & Development Day
October 27, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 19, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
October 17, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
August 03, 2022
Via
Benzinga
U.S. Stock Futures Gain Ahead of Services PMI; Crude Oil Drops Over 1%
August 03, 2022
Pre-open movers
Via
Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
August 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
May 24, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
May 06, 2022
Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
May 05, 2022
Upgrades
Via
Benzinga
A Peek Into The Markets: US Stock Futures Down Following Wednesday's Surge
May 05, 2022
Pre-open movers
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.